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BACKGROUND: Current international guidelines recommend the use of platinum-based chemotherapy with thoracic radiotherapy
(TRT) for patients with locally advanced non-small-cell lung cancer (NSCLC).
METHODS: Patients with unresectable stage IIIA or IIIB NSCLC were treated with nedaplatin (NP) at 50mgm
 2 and irinotecan (CPT)
at 60mgm
 2 on days 1 and 8 every 4 weeks for two to four cycles with concurrent TRT (2Gy per day, total 60Gy).
RESULTS: All 35 patients were able to receive a total of 60Gy. Adverse effects and events in chemotherapy with TRT were grade 3 or
4 anaemia, neutropenia and thrombocytopenia, which occurred in 3.0%, 32.8% and 6.0% of patients, respectively. There was no
grade 3 pneumonitis or oesophagitis. Adverse effects and events in chemotherapy alone were mild. There was no treatment-related
death. An overall response rate was 94.3%. The median progression-free and overall survivals were 13.0 and 36.0 months,
respectively. The 5-year disease-free and overall survival rates were 25.7% and 40.0%, respectively.
CONCLUSION: NP and CPT treatment with concurrent TRT is effective and safe for patients with unresectable, locally advanced
NSCLC.
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Locally advanced stage III non-small-cell lung cancer (NSCLC) can
be thought of as a two-compartment model: a local-regional
compartment in the chest and a distant compartment harbouring
potential micrometastases. At the most basic level, thoracic
radiation therapy (TRT) is directed towards the intrathoracic
tumour burden, whereas chemotherapy works to eradicate
systemic microscopic metastatic deposits below current levels of
detection by computerised tomography scanning or positron
emission imaging with fluorodeoxyglucose. Chemotherapy may
contribute a radiosensitising effect locally, as well as providing
cytoreduction of bulky locoregional disease. Four different
treatment paradigms have emerged in recent years for application
of chemoradiotherapy (CRT): sequential, concurrent, induction
chemotherapy followed by concurrent CRT and concurrent CRT
followed by consolidation chemotherapy (Gandara et al, 2005).
Current international guidelines recommend the use of platinum-
based chemotherapy with TRT for patients with locally advanced
NSCLC (Pfister et al, 2004). A randomised phase III study
comparing induction chemotherapy with concurrent CRT using
an identical chemotherapy regimen demonstrated that chemo-
therapy using cisplatin, vindesine and mitomycin C with con-
current TRT significantly improved survival in comparison with a
sequential approach such as chemotherapy followed by TRT
(Furuse et al, 1999). The study demonstrated that median survival
time (MST) and 5-year survival rate were 16.5 months and 16% in
the concurrent arm compared with 13.3 months and 9%,
respectively. However, increased toxicity was noted with con-
current therapy, primarily consisting of intensified toxicities
within the TRT field, notably oesophagitis with associated
nutritional problems and potential dehydration. There may also
be an increased risk of pneumonitis and severe myelotoxicities.
Thus, concurrent TRT may be too toxic for selected patient groups
with NSCLC, especially for elderly patients and those with poor
performance status (PS).
Nedaplatin (NP) is an analogue of cisplatin, showing relatively
low neurotoxicity and nephrotoxicity, and high in vivo bioavail-
ability, ensuring the position of NP as a primary chemotherapeutic
agent for the treatment of patients with advanced lung cancer
(Kameyama et al, 1990). Our previous phase I/II study of NP and
irinotecan (CPT) showed high activity against NSCLC, including a
31.0% response rate (RR), an MST of 341 days and a 1-year
survival rate of 45.2% (Oshita et al, 2003). Mild toxicities were also
demonstrated, and a subsequent phase II study of this combina-
tion demonstrated its efficacy and feasibility for elderly patients
with NSCLC (Oshita et al, 2004). Three-dimensional analysis
models have demonstrated a remarkable synergistic interaction of
concurrent NP with CPT (Kanzawa et al, 2001), and we expected
that infusion of the two drugs on the same day combined with
concurrent TRT would yield a stronger effect. Some patients with
locally advanced unresectable NSCLC have received sequential
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sTRT after completion of NP and CPT chemotherapy at the
Kanagawa Cancer Center. These patients experienced only mild
localised lung damage in the radiation field after completion of
full-dose TRT. These data suggested that chemotherapy using NP
and CPT would be feasible when combined with concurrent TRT.
Therefore, we conducted a phase II study to examine the feasibility
and effect of NP and CPT concurrent with TRT, planning to
combine TRT with the first course of NP and CPT chemotherapy.
PATIENTS AND METHODS
The institutional review board of the Kanagawa Cancer Center
reviewed and approved this study before commencement.
Patients
Patients with histologically or cytologically confirmed NSCLC were
registered. Eligibility criteria were clinical stage IIIA or IIIB,
cytologically proven N2, unresectable cancer, an expected survival
of at least 12 weeks, a TRT field less than half of the unilateral lung,
patient age o70 years, Eastern Cooperative Oncology Group PS
score p1, leukocyte count X4000 per ml, haemoglobin X10g per
100ml, platelet count X100000 per ml, total serum bilirubin
p1.5mg per 100ml, aspartate aminotransferase and alanine
aminotransferase p90IUl
 1, serum creatinine p1.5mg per
100ml and PaO2 X70torr. None of the patients had received
chemotherapy, radiotherapy or surgical resection previously.
Patients with pleural or pericardial effusion were excluded.
Written informed consent was obtained from every patient.
Chemotherapy and TRT
Nedaplatin was administered at a dose of 50mgm
 2 on days 1 and 8.
Irinotecan was also administered at a dose of 60mgm
 2 on days 1
and 8. Patients were given a 5-HT3 antagonist and dexamethasone
intravenously before administration of the anticancer drugs on
days 1 and 8. Subsequent cycles of chemotherapy were started
when the patients satisfied the organ function criteria: leukocyte
count X3000 per ml, neutrophil count X1500 per ml, platelet count
X75000 per ml and less than grade 1 non-haematological
toxicities, except alopecia. If the dose-limiting toxicity (DLT) was
reached, the dose of NP and CPT in the subsequent cycle was
reduced by 10mgm
 2. Dose reduction was allowed once, and
any patient who experienced DLT twice was withdrawn from
the protocol. Dose-limiting toxicity was defined as toxicity in
every cycle consisting of grade 4 neutropenia lasting 4 days or
more; grade 4 neutropenia with fever of 381C or higher; grade 4
thrombocytopenia; Xgrade 2 depression of PaO2; Xgrade 2
dyspnoea; or grade 3 or 4 other non-haematological toxicity,
except alopecia, nausea and vomiting. Physical examination, a
complete blood cell count, biochemical tests and chest radiography
were performed weekly. Chemotherapy was repeated for a
maximum of four cycles, unless the disease progressed, but was
stopped if the tumour response was judged to be stable disease
(SD) after two cycles.
Thoracic radiotherapy using photon beams from a linac or
microtron accelerator, with energy between 6 and 10MV at a single
dose of 2Gy once daily, 5 days per week, total 60Gy, was begun on
day 1 or 2 of the first cycle of NP and CPT chemotherapy. The
clinical target volume was based on conventional chest X-ray and
CT scans, and included the primary lesion (CTV1), involved lymph
nodes with a short diameter of 1cm or larger (CTV2) and the
ipsilateral pulmonary hilum and bilateral mediastinum area
(CTV3). Anterior and posterior parallel opposed fields encom-
passed the initial planned target volume (PTV), consisting of
CTV1–3, with the superior and inferior field margins extended
to 1.5cm and lateral field margins extended to 1.5cm to allow for
respiratory variation and fixation error. The spinal cord dose was
limited to 50Gy using oblique parallel opposed fields. When grade
4 leukopenia, neutropenia or thrombocytopenia, fever X381C,
grade 2 pneumonitis or other grade 3 or 4 non-haematological
toxicities appeared, radiation therapy was stopped until the
toxicities ameliorated.
Evaluation of response and toxicities
Tumour response was evaluated according to the RECIST criteria
(Therasse et al, 2000). Complete response (CR) was defined as
the complete disappearance of all evidence of tumour for at least
4 weeks. Partial response (PR) was defined as at least a 50%
reduction in the sum of the product of the two greatest perpendi-
cular diameters of all indicator lesions or a reduction of more than
50% in evaluable disease for at least 4 weeks, with no appearance
of new lesions or progression of any existing lesions. Progressive
disease (PD) was defined as at least a 25% increase in the tumour
area or the appearance of new lesions. All other outcomes were
classified as SD. Toxicities were evaluated according to the
National Cancer Institute-Common Toxicity Criteria ver. 2 criteria
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/
docs/ctcv20_4-30-992.pdf).
Study design
We chose an 80% RR as a desirable target level and a 60% RR as
uninteresting. The study design had power in excess of 95% and
o20% error, and therefore 13 assessable patients in the first step
and 22 in the second step were required according to the minimax
design of Simon (1989). We decided to stop the study if there were
fewer than nine responders in the first step. The regimen was
defined as active if there were 26 or more responders out of the
total of 35 patients. Overall, survival was estimated by the method
of Kaplan and Meier.
RESULTS
Patient characteristics
Between August 2002 and June 2005, 35 patients were registered in
the phase II study (Table 1). A total of 22 patients were registered
Table 1 Patient characteristics
No. of patients
Total 35
Age (years)
Median 62
Range (43–69)
Gender
Male 25
Female 10
PS (ECOG)
09
12 6
Pathology
Adenocarcinoma 22
Squamous cell carcinoma 10
Others 3
Clinical stage
IIIA 30
IIIB 5
Abbreviation: ECOG¼Eastern Cooperative Oncology Group.
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sfor assessment of response in the first stage. Of the 22 patients in
the first stage, 20 responded and 13 patients were registered in the
second stage. A total of 25 patients were male and 10 were female,
with a median age of 62 years (range 43–69 years). Nine patients
had a PS of 0 and 26 had a PS of 1. In all, 22 patients had
adenocarcinoma, 10 had squamous cell carcinoma and the
remaining patients had other cancers. A total of 30 patients had
clinical stage IIIA and five had stage IIIB. Every patient was proven
cytologically to have N2 disease by broncoscopic examination.
Treatment delivery
A total of 67 cycles were administered with concurrent TRT. After
completion of TRT, a total of 48 cycles were administered. A total
of 28 patients received three or four cycles of chemotherapy, and
the median number of chemotherapy cycles was four. Chemo-
therapy dose reduction was required in two patients in the second
cycle and in one patient in the fourth cycle because of grade 4
neutropenia lasting 4 days or more. Three patients were unable to
continue the second cycle of chemotherapy because of grade 2
pneumonitis in two and delayed neutropenia in one. The reasons
for discontinuing chemotherapy after two cycles were PD (bone
metastasis) in two cases and patient refusal in two cases. All 35
patients were able to receive a total of 60Gy of TRT.
Toxicities
Adverse effects and events in cycles 1 and 2 of chemotherapy with
concurrent TRT are summarised in Table 2. Grade 3 or 4 anaemia,
leukopenia, neutropenia and thrombocytopenia occurred in 3.0,
38.8%, 32.8% and 6.0%, respectively. There were no grade 4
toxicities, except for leukopenia and neutropenia. There was no
grade 3 pneumonitis or oesophagitis. Adverse effects and events in
cycles 3 and 4 of chemotherapy are summarised in Table 3. Grade
3 or 4 anaemia, leukopenia, neutropenia and thrombocytopenia
occurred in 10.4%, 35.4%, 41.7% and 16.7%, respectively. There
were no grade 3 or 4 non-haematological toxicities, or any case of
treatment-related death.
Response and survivals
One patient achieved CR, 32 achieved PR and 2 showed SD, and
the overall RR in this series was 94.3% (95% confidence interval
86.6–100%). The median progression-free survival was 13.0
months (range 4.6 to 91.0þ months) and 5-year disease-free
survival rate was 25.7% (Figure 1). The MST was 36.0 months
(range 8.0 to 91.0þ months) and the 1-, 3- and 5-year survival
rates were 88.6%, 51.4% and 40.0%, respectively (Figure 1).
Table 2 Adverse effects and events in chemotherapy and concurrent
thoracic radiation
Grade (NCI-CTC ver.2)
Toxicity 0 1 2 3 4
Percentage
of G3 and 4
Haemoglobin 9 46 10 2 0 3.0
Leukocytes 5 7 29 25 1 38.8
Neutrophils 8 14 23 18 4 32.8
Platelets 32 27 4 4 0 6.0
Bilirubin 57 8 2 0 0 —
Creatinine 67 0 0 0 0 —
SGOT 55 11 1 0 0 —
SGPT 49 16 2 0 0 —
Fatigue 0 60 6 1 0 1.5
Nausea/vomiting 46 17 3 1 0 1.5
Diarrhoea 44 23 0 0 0 —
Pneumonitis 58 5 4 0 0 —
Fever 59 7 1 0 0 —
Febrile neutropenia 61 — — 6 0 9.0
Neuropathy–sensory 64 3 0 0 0 —
Alopecia 44 23 0 0 0 —
Oesophagitis 36 28 3 0 0 —
Gastritis 62 5 0 0 0 —
Cystitis 66 1 0 0 0 —
Sense of smell/dysgeusia 59 8 0 0 0 —
Constipation 61 6 0 0 0 —
Stomatitis 64 3 0 0 0 —
Epistaxis 66 1 0 0 0 —
Abbreviations: NCI-CTC ver.2¼National Cancer Institute-Common Toxicity
Criteria; SGOT¼serum glutamic oxaloacetic transaminase; SGPT¼Serum glutamic
pyruvic transaminase.
Table 3 Adverse effects and events in 3 and 4 courses of chemotherapy
Grade (NCI-CTC ver.2)
Toxicity 0 1 2 3 4
Percentage
of G3 and 4
Haemoglobin 4 27 12 5 0 10.4
Leukocytes 10 7 14 15 2 35.4
Neutrophils 13 4 11 12 8 41.7
Platelets 24 10 6 7 1 16.7
Bilirubin 45 2 1 0 0 —
Creatinine 47 1 0 0 0 —
SGOT 42 6 0 0 0 —
SGPT 40 8 0 0 0 —
Fatigue 0 45 3 0 0 —
Nausea/vomiting 38 10 0 0 0 —
Diarrhoea 35 13 0 0 0 —
Pneumonitis 35 9 4 0 0 —
Fever 47 1 0 0 0 —
Febrile neutropenia 46 — — 2 0 4.0
Neuropathy–sensory 48 0 0 0 0 —
Alopecia 17 31 0 0 0 —
Oesophagitis 44 4 0 0 0 —
Gastritis 45 3 0 0 0 —
Cystitis 48 0 0 0 0 —
Sense of smell/dysgeusia 43 5 0 0 0 —
Constipation 46 2 0 0 0 —
Stomatitis 47 1 0 0 0 —
Abbreviations: NCI-CTC ver.2¼National Cancer Institute-Common Toxicity
Criteria; SGOT¼serum glutamic oxaloacetic transaminase; SGPT¼Serum glutamic
pyruvic transaminase.
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Figure 1 Progression-free (a dotted line) and overall (a bold line)
survival curves constructed using the Kaplan–Meier method. The median
progression-free survival was 13.0 months (range 4.6 to 91.0þ months)
and 5-year disease-free survival rate was 25.7%. The MST was 36.0 months
(range 8.0 to 91.0þ months) and 5-year survival rates were 40.0%.
Nedaplatin, irinotecan and radiation for lung cancer
F Oshita et al
1327
British Journal of Cancer (2010) 103(9), 1325–1330 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sSites of first failure and second treatments
In all, 26 patients had recurrences during follow-up. The first
failure was observed at the primary site in the radiation field in
nine patients, and distant failure was detected in 17 patients
(Table 4). Five of six patients, in whom the site of first failure was
the brain, received whole-brain irradiation. In all 15 patients
received second-line chemotherapies, such as docetaxel-based
chemotherapy in 6, gefitinib (Gef) in 6 and others in 3. Two
patients received radiotherapy to metastatic sites and five received
supportive care only. Four patients had second primary malig-
nancies: two in the oesophagus, one in the kidney and one in the
lung. Three of them received surgical resections and are alive and
disease free.
DISCUSSION
Clinical trials and a meta-analysis have shown that concurrent
chemotherapy and TRT affords outcomes superior to those of
sequential therapy (Furuse et al, 1999; Zatloukal et al, 2004;
Fournel et al, 2005). As the cisplatin and etoposide combination
can be given at full dose, concurrent with TRT, this doublet is
considered as the standard option for CRT protocols, as shown in
two sequential, non-randomised studies by the Southwest Onco-
logy Group (SWOG) (Albain et al, 2002; Gandara et al, 2003).
However, there have been no phase III comparisons of different
CRT regimens. Therefore, a specific standard regimen cannot be
established at this time.
The present regimen comprising NP and CPT with concurrent
TRT showed extremely high activity. Both the MST and 5-year
survival rate were the best recorded so far for a phase II study in
patients with unresectable locally advanced NSCLC. Only four
patients died within 1 year, and nine patients, accounting for a
quarter of the total subjects, survived for over 5 years without
tumour recurrence. We anticipated the toxicities that would be
induced by this combined modality, and administered the NP in
divided doses on days 1 and 8, unlike previous studies (Oshita
et al, 2003, 2004). As three-dimensional analysis models have
demonstrated that concurrent exposure to NP and CPT produces a
marked synergistic interaction (Kanzawa et al, 2001), it was
considered that a more potent effect would be achieved by infusing
the two drugs on the same day.
The present regimen comprising NP and CPT with concurrent
TRT also demonstrated high feasibility. Haematological toxicities
were mild, and oesophagitis and pneumonitis were manageable.
Grade 3/4 neutropenia occurred only in 32.8% of patients, and
grade 3 febrile neutropenia occurred in only 9.0% during the
concurrent phase with TRT. Every febrile episode was improved by
antibiotics, and every patient was able to receive a subsequent
cycle of chemotherapy. Other than febrile neutropenia, grade 3
non-haematological toxicities included only one episode each
of fatigue and vomiting, and there was no grade 3/4 pneumonitis
or oesophagitis. Nine patients experienced grade 1/2 pneumonitis
in the concurrent phase of CRT, and two of them were unable to
progress to the second cycle of NP and CPT chemotherapy,
although they did receive the full dose of TRT. Pneumonitis
induced by combination therapy with TRT and CPT was
anticipated in some studies. Wu and Choy (2002) reviewed some
trials and recommended CPT as a radiosensitiser, but gave a
warning of occurrence of pneumonitis. Full dose of cisplatin and
CPT with concurrent TRT resulted in 10% of patients with grade 3
pneumonitis in a Japanese trial (Fukuda et al, 2007) and
concurrent TRT with carboplatin and CPT resulted in a 42%
incidence of grade 2 or more radiation pneumonitis in a recent
American study (Bastos et al, 2010). However, pneumonitis in this
study was grade 2 or less and only one late grade 3 pneumonitis
occurred in a study of weekly CPT and cisplatin treatment with
concurrent TRT (Langer et al, 2007). These data suggested that
TRT with full dose of platinum and CPT might induce some
amount of severe radiation pneumonitis but that with weekly or
divided platinum and CPT, as in our study, might be able to
decrease the grade of pneumonitis. There was no treatment-related
death, and the shortest survival time was 8 months. A Japanese
trial of docetaxel consolidation therapy after cisplatin, vinorelbine
and concurrent TRT in patients with unresectable stage III NSCLC
reported grade 3/4 neutropenia, oesophagitis and pneumonitis in
63.9%, 11.3% and 3.1% of patients, respectively, in the phase of
cisplatin and vinorelbine with concurrent TRT (Sekine et al, 2006).
Another recent Japanese trial of cisplatin and S-1 with concurrent
TRT in patients with unresectable stage III NSCLC reported grade
3/4 neutropenia, grade 3 oesophagitis and grade 3 pneumonitis in
32.0%, 10.0% and 5.0% of patients, respectively, in the cisplatin
and S-1 with concurrent TRT phase (Ohyanagi et al, 2009). The
SWOG 9504 also demonstrated moderate toxicities, such as grade 3
or 4 neutropenia, oesophagitis and pneumonitis developing in
74%, 17% and 5%, respectively, in the cisplatin and etoposide with
concurrent TRT phase (Gandara et al, 2003). These three trials
demonstrated MSTs of 26, 30 and 33.1 months, which are
comparable with the results of the present study. Thus, the
present combined modality yielded favourable outcomes with low
toxicities. This powerful NP and CPT combination chemotherapy
also demonstrated high safety in lung cancer patients, with
multiple risk factors in a retrospective analysis (Oshita et al,
2007). A total of 31 NSCLC patients with multiple high-risk factors
were treated with NP at 50mgm
 2 and with CPT at 50mgm
 2 on
days 1 and 8 every 4 weeks. With regard to toxicities, 7 (8.4%) and
11 cycles (13%) were associated with grade 4 neutropenia and
grade 3 febrile neutropenia, respectively. Each of the toxicities was
controllable, and there was no treatment-related death. One patient
achieved CR, 13 achieved PR and the overall RR was 45.2%.
Nedaplatin and CPT with concurrent TRT yielded a high RR and
good outcome, but 26 of the 35 treated patients had tumour
recurrence. Recurrent lesions were located in both the primary
irradiated field of the lung and in distant organs such as the brain
or bones. Tumour regrowth within the radiated field and brain
metastasis were detected as the first sites of recurrence in nine and
six patients, respectively. Thus, the present treatment, although
powerful, seems to be somewhat insufficient for both locoregional
control and suppression of distant metastasis. Brain metastasis as
the first site of relapse was observed in six patients within 1 year.
To suppress brain metastasis, prophylactic cranial irradiation after
completion of CRT could be considered. This approach has been
established in the treatment of small-cell lung cancer, but has
not been recommended for stage III NSCLC. As only 23.1% of
our study patients demonstrated a single brain metastasis,
prophylactic radiotherapy should be considered carefully.
The use of an additional chemotherapy component remains
investigational. The consolidation chemotherapy approach and the
Table 4 Sites of initial failure
Patients
First site of failure No. Percentage
Local 9 34.6
Distant
Brain 6 23.1
Bone 4
a 15.4
Lung 4
a 15.4
Cervix 3 11.5
Liver 1 3.8
Kidney 1 3.8
Adrenal 1 3.8
aThree patients had recurrence in both bone and lung.
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under investigation. Careful consideration must be given to the
exact role a novel therapeutic agent is expected to have in a
combined modality therapy setting; that is, in addition to CRT,
should the agent be a single drug active against NSCLC, a
radiosensitising agent or an agent to control distant micrometas-
tasis? Additional data regarding docetaxel consolidation have been
obtained from the SWOG and also from trials in Japan. A non-
randomised study by the SWOG evaluated docetaxel consolidation
after cisplatin and etoposide CRT, and suggested that 75mgm
 2
docetaxel was better tolerated without loss of efficacy (Gandara
et al, 2003). In a phase II trial in Japan, 97 patients with
unresectable stage III NSCLC received docetaxel consolidation
after concurrent CRT using cisplatin and vinorelbine for three
cycles (Sekine et al, 2006). Only 37% of patients completed all
three cycles of docetaxel. Pneumonitis was the most common
reason for early discontinuation, and four patients died of this
complication.
Tyrosine kinase inhibitors directed against epidermal growth
factor receptor (EGFR) have been shown to be effective for the
treatment of advanced NSCLC (Fukuoka et al, 2003). A retro-
spective study has demonstrated that NSCLC patients with EGFR
mutation have a better outcome with Gef treatment than do
patients with wild-type EGFR (Mitsudomi et al, 2005). A
randomised phase III study comparing Gef with standard
carboplatin plus paclitaxel has demonstrated that Gef conferred
significantly superior progression-free survival as first-line chemo-
therapy in patients with EGFR mutation (Mok et al, 2009).
Furthermore, another phase III trial demonstrated that chemo-
therapy-naı ¨ve patients with EGFR have longer progression-free
survival if they were treated with Gef than if they were treated with
cisplatin and docetaxel (Mitsudomi et al, 2010). These data
suggested that Gef is essential for NSCLC patients with EGFR
mutation. With regard to the use of EGFR tyrosine kinase
inhibitors given concurrently with TRT or CRT, the Cancer and
Leukemia Group B30106 is a stratified phase II trial testing Gef
concurrently with TRT alone or with CRT in patients with NSCLC
(Ready et al, 2004), but the feasibility of Gef combined with CRT or
TRT has not been established. Our recent study demonstrated that
sequential Gef treatment added to NP and CPT combination
chemotherapy conferred a survival benefit (32.1%, 2-year survival
rate) in 28 elderly patients with advanced NSCLC, whose EGFR
mutation was unknown (Oshita et al, 2008). Thus, it was suggested
that CRT followed by Gef maintenance strategy should be explored
for locally advanced NSCLC with EGFR mutation.
In conclusion, NP and CPT with concurrent TRT have been
shown to have high activity with high safety. A phase III study will
be required to establish this regimen as a new standard therapy
against unresectable locally advanced NSCLC.
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